Table II.

Test Ags^a

Ag	Description/Source	Derivation, Comments
PI	Lilly Pharm.	E. coli, full-length*
IA-2	Bayer Pharm.	E. coli, “ICA512”*
GAD65	Peptide 524	SRLSKVAPVIKARMMEYGTT*
HSP60	Peptide 277	VLGGGCALLRCIPALDSLTPANED*
ICA69	β-isoform	E. coli*
	α-isoform	Baculovirus^†
	ICA69-36 “Tep69”	AFIKATGKKEDE, homolog BSA-148*
	ICA69-202	KNFDKLKMDVCQ, homolog BSA-394^†
	ICA69-350	SEEGACLGPVAG, homolog BSA-193^†
BSA	Sigma	Fraction V*
	BSA-148 “ABBOS”	FKADEKKFWGKYL, homolog ICA69-36*
	BSA-394	TSVFDKLKHLVD, homolog ICA69-202^†
	BSA-193	EDKGACLLPKIE, homolog ICA69-350^†
Tetanus toxoid	PMC Canada	Pharmaceutical grade*
OVA	Sigma	Fraction V*
	OVA152	EYQDNRVSFLGHFI*
Human hemoglob.	Sigma	Purified^†
Human cytochr. c	Sigma	Purified^†
Human actin	Sigma	Purified^†

a Description of the test antigens/peptides used, not all could be tested in all study subjects. Eleven Ags (marked with an asterisk) were used routinely; the remainder (marked with a dagger) were tested only in subsets of probands to answer specific questions. Peptide names indicate origin and N-terminal amino acid position. Residues printed in bold identify homologies described in the text.